Catalog No.
Product Name
Application
Product Information
Citations
-
Prostaglandin Receptor Inhibitor
Ciproquazone is a prostaglandin receptor inhibitor that effectively reduces prostaglandin biosynthesis. It exhibits a relative inhibitory potency that falls between indomethacin and aspirin, making it a relevant tool for research in inflammatory processes. Its reversible mode of action allows for precise modulation in experimental settings, facilitating studies in pain management and related pharmacological applications. -
PGF2α Receptor Activator
(Rac)-SC-31391 is a potent activator of the PGF2α receptor. This prostaglandin analog enhances bladder muscle contractility, significantly augmenting twitch responses in the guinea pig detrusor muscle. In human bladder muscle, (Rac)-SC-31391 induces contractions through selective PGF2α receptor activation, making it valuable for research into bladder function and related disorders. -
Prostaglandin Receptor
19(R)-hydroxy Prostaglandin E2 is a selective agonist targeting the prostaglandin EP2 receptor. Known for its potent smooth muscle relaxant properties, it demonstrates an EC50 value of 200 nM in relaxing cat tracheal rings that express EP2 receptors. This compound is valuable for research applications focused on smooth muscle physiology and prostaglandin signaling pathways. -
Prostacyclin Analogue
Ciprostene is a prostacyclin analogue that primarily targets the prostacyclin receptor. It effectively inhibits adenosine diphosphate-induced platelet aggregation, making it a valuable reagent for research on cardiovascular disorders. This compound is particularly useful in studies related to peripheral vascular disease and thrombosis. -
Tafluprost Derivative
9-Keto tafluprost is a derivative of tafluprost, which functions as an agonist of prostaglandin receptors. This compound exhibits significant activity in lowering intraocular pressure, making it relevant in the study and treatment of glaucoma. It is utilized in research exploring the pharmacological effects of prostaglandin analogs and their mechanisms in ocular conditions. -
Prostaglandin D2 Prodrug
Prostaglandin D2 methyl ester is a prodrug of Prostaglandin D2, primarily targeting the PGD2 receptors. It exhibits binding affinities (Ki values) of 160 nM for murine CRTH2, 175 nM for murine DP, 460 nM for human CRTH2, and 270 nM for human DP. This compound is useful in research applications investigating inflammatory responses, allergic reactions, and sleep regulation, highlighting its importance in pharmacological studies related to prostaglandin signaling pathways. -
Anti-arrhythmias Drug
Ro 22-9194 is an anti-arrhythmic agent that inhibits thromboxane A2 (TXA2) synthetase activity, affecting platelet aggregation in both rabbit and human models. This compound demonstrates significant efficacy in suppressing various types of model arrhythmias. Additionally, Ro 22-9194 possesses non-cholinergic cardiac depressant properties, complemented by its vasodilatory effects, making it valuable for cardiovascular research applications. -
TXA2 Antagonist
L 657925 is a potent thromboxane A2 (TXA2) antagonist, selectively inhibiting TXA2-mediated signaling pathways. This compound effectively abolishes the ONO 11113-induced transient increase in intracellular calcium concentration, making it a valuable tool for studying TXA2-related physiological processes. Its application spans research into cardiovascular diseases and platelet function, contributing to a deeper understanding of thromboxane's role in vascular biology. -
Prostaglandin Analogue
17-Trifluoromethylphenyl-13,14-dihydro trinor prostaglandin F1α is a saturated prostaglandin analogue that targets the human prostaglandin F receptor (hFP receptor). It exhibits a notable affinity and selectivity for this receptor, demonstrating an EC50 value of 85 nM. This compound is useful in research applications focused on prostaglandin signaling pathways and the development of therapeutics targeting reproductive functions and vascular biology. -
Prostaglandin Receptor
ONO 207 is a potent analog of Prostaglandin F2α, specifically designed to target prostaglandin receptors. It demonstrates enhanced luteolytic activity in hamsters, exhibiting a potency five times greater than that of PGF2α. With an ED50 value of 1.5 μg/100 g, ONO 207 is a valuable reagent for studying reproductive physiology and luteolysis in various biological research contexts. -
TX Synthetase Inhibitor
LG 82-4-01 is a selective thromboxane (TX) synthetase inhibitor, exhibiting an IC50 of 1.3 μM. This compound effectively inhibits the synthesis of thromboxanes, which are implicated in various cardiovascular and inflammatory processes. LG 82-4-01 is useful in studying TX-mediated pathways and assessing potential therapeutic interventions in related diseases. -
Prostaglandin F2α Analogue
16-Phenoxy tetranor Prostaglandin F2α methyl ester is a metabolically stable analogue of Prostaglandin F2α, designed to bind selectively to the FP receptor. This compound functions as a prodrug that can be hydrolyzed to release its bioactive free acid form, enabling its use in various biological assays. Its properties make it suitable for research applications focused on reproductive physiology and other areas involving prostaglandin signaling. -
PGD1 analog
Prostaglandin D1 alcohol is a synthetic analog of Prostaglandin D1 (PGD1) featuring a primary alcohol substitution at the C-1 position. This compound maintains the biological properties of PGD1, engaging the prostaglandin receptors to exhibit various physiological effects. It is utilized in molecular research related to inflammation, vascular biology, and neuroprotection, aiding in the study of prostaglandin-mediated signaling pathways. -
Analog of Prostacyclin
Prostaglandin K1 is a structural analog of prostacyclin, primarily acting on the EP1 receptor. It exhibits an EC50 of 2800 nM and a Ki of 2800 nM, indicating its affinity for this target. This compound serves as a valuable tool in research focused on prostanoid signaling pathways and their implications in various physiological and pathological processes. -
Prostaglandin Receptor
9-keto Fluprostenol is an analog of prostaglandin E2 (PGE2) designed to target the prostaglandin receptor with enhanced potency and prolonged half-life. This compound, an oxidation derivative of fluprostenol, acts primarily on the FP receptor and is expected to exhibit significant affinity for EP receptors, functioning as a PGE2 agonist. It holds potential for research applications related to inflammation, reproductive biology, and other physiological processes mediated by prostaglandins. -
Fluprostenol Analog
Fluprostenol methyl ester is an F-series prostaglandin analog primarily targeting the prostaglandin receptors. It demonstrates luteolytic activity and is utilized extensively in veterinary medicine for reproductive management. This compound is essential for research applications focused on reproductive physiology and the regulation of the estrous cycle in animals. -
Prodrug
Prostaglandin E1 ethyl ester is a prodrug of Prostaglandin E1 (PGE1), a potent ligand for prostaglandin receptors. This compound is known for its ability to induce vasodilation and inhibit platelet aggregation, making it valuable in vascular research. It is utilized in studies related to cardiology, reproductive health, and conditions of impaired blood flow. -
Prostaglandin FP Agonist
AR-102 isopropyl ester is a second-generation prostaglandin FP agonist that targets the FP receptor to effectively lower intraocular pressure. This compound exhibits potent biological activity in research applications related to glaucoma and ocular hypertension, making it a valuable tool for studying therapeutic interventions in these conditions. Its specific mechanism of action supports the exploration of novel treatments aimed at managing elevated ocular pressure. -
Prostaglandin E2 Inhibitor
Camonagrel is a potent inhibitor of Prostaglandin E2, targeting thromboxane synthase to decrease the biosynthesis of thromboxane. This compound exhibits significant anti-inflammatory properties and is useful in research applications focused on cardiovascular disease and inflammation pathways. Its inhibition of Prostaglandin E2 makes it a valuable reagent for studies investigating platelet aggregation and vascular function. -
FP Receptor Inhibitor
CAY10509 is a potent inhibitor of the FP receptor, characterized by an IC50 value of 30 nM. As a PGF2α analog, it serves as a valuable tool for investigating physiological regulatory mechanisms associated with prostaglandin signaling. This reagent is suitable for applications in pharmacological studies and the exploration of inflammatory processes in various biological systems. -
IP Receptor Agonist
MRE-269-d7 is a deuterium-labeled derivative of MRE-269, which serves as an active metabolite of selexipag. This compound functions as a selective agonist of the IP receptor, playing a critical role in research related to pulmonary arterial hypertension and vascular biology. Its unique properties make it suitable for studies investigating the modulation of prostacyclin pathways and their physiological effects. -
Stereoisomer
16(S)-Iloprost is a stereoisomer of Iloprost, primarily acting as a potent inhibitor of platelet aggregation. It demonstrates significant biological activity with an IC50 value of 3.5 nM, indicating its effectiveness in reducing platelet aggregation. Additionally, it exhibits balanced binding to platelet membrane receptors, with a dissociation constant (Kd) of 13.4 nM. This compound is utilized in research applications focusing on cardiovascular diseases and hemostatic disorders. -
Prostaglandin Receptor
TASP0412098 is a potent and selective antagonist of the prostaglandin receptor CRTH2/DP2, exhibiting a high binding affinity with an IC50 of 2.1 nM and functional activity with an IC50 of 12 nM. This compound demonstrates potential anti-inflammatory effects and may be beneficial in suppressing asthma, as evidenced by its efficacy in mouse and guinea pig bronchial asthma models. TASP0412098 is a valuable tool for researchers investigating the role of prostaglandin receptors in respiratory conditions and inflammation. -
Partial Agonist Of IP Receptors
Taprostene sodium is a partial agonist of prostanoid IP receptors, demonstrating a unique mechanism of action in modulating vascular and cardiac functions. This compound exhibits significant cardioprotective properties and can interact additively with Prostaglandin E2 (PGE2) and selective EP2 agonists. Taprostene sodium serves as a valuable tool in cardiovascular research, particularly in studies focused on vascular biology and cardiac health. -
Prostaglandin Receptor
11-keto Fluprostenol is a structural analog of prostaglandin D2 (PGD2) designed to enhance potency and extend its half-life. This compound primarily targets the FP receptor and demonstrates significant biological activity as a potent analog of PGF2α. In addition, 11-keto Fluprostenol shows moderate binding affinity for the CRTH2/DP2 receptor, with minimal activity at the DP1 receptor. Its unique profile makes it a valuable tool for research involving prostaglandin signaling pathways and related biological processes. -
Thromboxane Receptor Antagonist
Linotroban is a potent, orally active thromboxane receptor antagonist (TXRA), classified as a non-prostanoid. It demonstrates significant antiplatelet activity, making it a valuable antithrombotic agent in research applications. Linotroban is utilized in studies evaluating platelet aggregation and cardiovascular disease, contributing to a better understanding of thrombotic processes. -
Prostaglandin Receptor Inhibitor
MF-592 is a potent inhibitor of the prostaglandin E2 (PGE2) receptor, demonstrating an IC50 value of 3 nM. This compound exhibits favorable pharmacokinetic properties in both rat and dog models, making it a valuable tool for research in inflammation and pain modulation. Its selective inhibition of PGE2 signaling pathways supports studies aimed at understanding various biological processes and developing therapeutic strategies for related diseases. -
P450 ω-Hydroxylase Inhibitor
12(S)-Hydroxy-16-heptadecynoic acid is a mechanism-based inhibitor of cytochrome P450 ω-hydroxylase, effectively targeting this enzyme to modulate its activity. With a Ki value of 1.8 μM, it demonstrates significant inhibitory potency against prostaglandin ω-hydroxylase. This compound is valuable for research applications involving metabolic studies and the modulation of lipid biosynthesis pathways. -
Prostaglandin Receptor
Lythrine is an alkaloid that targets prostaglandin receptors, demonstrating inhibition of prostaglandin synthetase with an IC50 of 469 μM. This compound is valuable for research applications focused on inflammation and pain pathways, as well as studying the role of prostaglandins in various biological processes. Its potential effects on the prostaglandin synthesis pathway make it a relevant tool for exploring therapeutic strategies in related disorders. -
PGHS-2 Inhibitor
12(S)-HPEPE is a potent inhibitor of prostaglandin endoperoxide synthase-2 (PGHS-2), functioning as a lipoxygenase product. This compound demonstrates significant anti-inflammatory activity by reducing interleukin 1h (IL-1h)-induced PGHS-2 expression in human lung microvascular endothelial cells. Its utility in research includes the investigation of inflammatory processes and the modulation of PGHS-2 activity, providing valuable insights into therapeutic strategies for inflammatory diseases. -
Prostaglandin Receptor
(+)-15-epi Cloprostenol is an enantiomer of cloprostenol that acts as an agonist for the prostaglandin F2α (PGF2α) receptor. While it has significantly lower activity as an FP receptor ligand compared to its counter enantiomer, 15(R)-cloprostenol, its unique structural features warrant further investigation into its biological interactions. This compound may have potential applications in research exploring the modulation of prostaglandin signaling pathways and its implications in various physiological and pathological processes. -
PGF1α Analog
3-Methoxy prostaglandin F1α is a PGF1α analog that exhibits similar biological activity, influencing various physiological processes. This compound may be metabolized by naturally occurring extracellular antibiotic resistance genes (eARGs), highlighting its relevance in studies of antibiotic resistance dynamics in the gut microbiome. Its applications include the investigation of prostaglandin-related pathways in gastrointestinal health and antibiotic resistance mechanisms. -
Prostaglandin Receptor
Prostaglandin K2 (PGK2) primarily targets prostaglandin receptors and is characterized as a 9,11-diketone derived from the oxidation of PGE2 or PGD2. Its biological existence remains uncertain; however, PGK2 demonstrates resistance to metabolism by 15-hydroxy PGDH in vitro. This unique stability may facilitate research into its potential roles in prostaglandin signaling and related pathways. -
CRTh2 Antagonist
CRTh2 Antagonist 2 is a selective and potent CRTh2 receptor antagonist, exhibiting an IC50 of ≤10 nM. This compound is primarily utilized in research related to androgenic alopecia, offering valuable insights into the modulation of hair growth and related pathways. Its high specificity makes it an essential tool for investigating the therapeutic potential in hair loss disorders. -
TXA/PG-END Receptor Antagonist
L-641953 is a selective antagonist of the thromboxane-prostaglandin endoperoxide receptor (TXA/PG-END). It effectively inhibits bronchoconstriction induced by arachidonic acid, showcasing its potential in respiratory physiology studies. This compound is particularly relevant for research in cardiovascular diseases, offering insights into the modulation of vascular responses and inflammation. -
Prostaglandin Analogue
5-trans-Fluprostenol is a synthetic prostaglandin analogue that acts on the prostaglandin receptors. It exhibits significant biological activity in modulating vascular function and influencing smooth muscle contraction. This compound is utilized in research applications related to cardiovascular physiology and reproductive health studies, providing insights into prostaglandin signaling pathways. -
Eyelash Enhancing Agent
Tafluprost ethyl amide is a prostaglandin derivative primarily known for its role as an eyelash enhancing agent. It effectively reduces intraocular pressure (IOP) and promotes eyelash growth, making it useful in the development of antiglaucoma ophthalmic formulations. This compound is valuable for researchers investigating treatments for ocular conditions and cosmetic applications related to eyelash enhancement. -
FP Receptor Agonist
N-Cyclopropyl methyl bimatoprost is a potent agonist of the Prostaglandin F2α Receptor (FP receptor). This compound has demonstrated significant biological activity in reducing intraocular pressure, making it a valuable reagent in glaucoma research. Its mechanism of action supports the exploration of therapeutic strategies for managing ocular hypertension and related conditions. -
EP Receptor Agonist
9-Keto Travoprost is an EP receptor agonist, functioning primarily through the stimulation of prostaglandin E receptors. This compound is valuable for investigating endocrine-related mechanisms and has potential applications in research focused on ocular health and intraocular pressure regulation. Its ability to selectively engage EP receptors makes it a useful tool for studying pharmacological responses in various biological contexts. -
Thromboxane A2 Receptor Antagonist
Vapiprost is a thromboxane A2 receptor (TXA2 receptor) antagonist that effectively inhibits thromboxane-mediated platelet aggregation and ATP release. It demonstrates a potent inhibitory effect on the aggregation induced by U-46619, collagen, or arachidonic acid (AA) with an IC50 of less than 2.1×10^-8 M. Vapiprost is utilized in research applications focused on cardiovascular studies and platelet function, contributing valuable insights into thromboxane signaling pathways. -
Prostaglandin Receptor Antagonist
CRTH2-IN-1 is a selective antagonist of the prostaglandin D2 receptor, also known as CRTH2, with an IC50 value of 6 nM in human DP2 binding assays. This compound is utilized in research focused on elucidating the role of DP2 in various biological pathways, including inflammation and immune response. Its properties make it a valuable tool for investigating therapeutic strategies in conditions associated with prostaglandin signaling. -
Prostaglandin Analog
16(R)-AFP 07 free acid is a potent prostaglandin analog targeting the IP receptor, which is critical for inhibiting platelet aggregation and promoting vasodilation in the pulmonary vascular system. As a 7,7-difluoroprostacyclin derivative, it exhibits high selectivity and potency for the IP receptor (Ki = 0.561 nM). While its affinity for EP receptors is significantly lower, with Ki values exceeding 100 nM for EP1-3 and >10 nM for EP4, the full extent of 16(R)-AFP 07's biological activity, particularly at the IP and EP receptors, warrants further investigation. This compound is relevant for studies exploring vascular functions and anti-thrombotic applications. -
Prostaglandin Receptor Antagonist
(S)-AL-8810 is a potent and selective antagonist of the prostaglandin F (FP) receptor, characterized as an 11β-fluoro analog of PGF2α. This compound is the C-15 epimer of AL-8810, possessing the (S) or "natural" configuration at C-15. (S)-AL-8810 is primarily utilized in research involving reproductive biology and pharmacology, offering insights into the modulation of prostaglandin signaling pathways. -
EP4 Receptor Antagonist
ONO-AE3-208 sodium salt is a selective antagonist of the EP4 receptor, exhibiting a Ki value of 1.3 nM, which demonstrates its strong binding affinity. This compound has minimal effect on EP3, FP, and TP receptors, with Ki values of 30 nM, 790 nM, and 2400 nM, respectively. ONO-AE3-208 sodium salt has shown significant biological activity in inhibiting cell invasion, migration, and metastasis in prostate cancer research applications. -
Prostaglandin Receptor
17-Trifluoromethylphenyl trinor Prostaglandin F2α is a potent agonist of the prostaglandin FP receptor, known for its significant biological activity as a luteolytic agent. This compound features a trifluoromethyl-substituted aromatic ring structure, akin to the phenoxy ring of travoprost, contributing to its efficacy in lowering intraocular pressure. Its pharmacological profile suggests potential applications in the treatment of glaucoma and other conditions where modulation of prostaglandin pathways is beneficial. Its luteolytic potency is comparable to or surpasses that of established agents such as fluprostenol and cloprostenol. -
TP receptor antagonist
TP receptor antagonist-1 is a selective antagonist of the thromboxane A2 receptor (TP receptor), exhibiting IC50 values of 9.46 μM for TPa and 8.49 μM for TPb. This compound plays a significant role in modulating thromboxane-related signaling pathways, making it valuable for investigating cardiovascular diseases. Researchers can utilize TP receptor antagonist-1 to explore therapeutic strategies targeting TP receptor-mediated effects in various cardiovascular conditions. -
Metabolite
O-Desmethyl-N-deschlorobenzoyl Indomethacin is a metabolite of the non-steroidal anti-inflammatory drug indomethacin, acting as a cyclooxygenase (COX) inhibitor. This compound demonstrates significant biological activity by reducing the viability of HL-60 leukemia cells in the presence of glucose oxidase at a concentration of 600 μM. It serves as a valuable reagent in research focused on synthesizing prostaglandin D2 receptor antagonists and elucidating the metabolic pathways of NSAIDs. -
PGD2 Analog
2,3-Dinor-11beta-prostaglandin F2alpha is a key metabolite of PGD2, functioning primarily as a biomarker for elevated PGD2 levels. It is notably excreted in higher amounts in patients with mast cell activation disease (MCAD) and asthma, demonstrating a positive correlation with deteriorating lung function. This compound serves as a valuable tool for researchers studying inflammatory conditions and mast cell-related pathologies. -
Prostaglandin Receptor Inhibitor
(±)12-HEPE is a prostaglandin receptor inhibitor produced through the non-enzymatic oxidation of eicosapentaenoic acid (EPA), comprising equal parts of the 12(S)- and 12(R)- isomers. The 12(S) isomer primarily mediates its biological effects in mammalian systems, demonstrating significant inhibition of platelet aggregation with an IC50 of 24 μM, comparable to that of 12-HETE. Additionally, (±)12-HEPE effectively inhibits U46619-induced contraction in rat aorta, exhibiting IC50 values ranging from 8.6 to 8.8 μM, making it valuable for research in cardiovascular and inflammatory responses. -
Acetylation Inhibitors
O-Acetylsalicylhydroxamic acid is an acetylation inhibitor targeting prostaglandin H2 synthase (PGHS). It effectively suppresses prostaglandin E2 (PGE2) synthesis and inhibits the cyclooxygenase activity of PGHS in vitro. The compound specifically requires the active site residue Ser-529 for its action on human PGHS-1, with the S529A mutant displaying resistance to its inactivating effects, making it a valuable tool for research in inflammation and pain pathways.
